BIOLINERX LTD-SPONS ADR (BLRX)
US09071M2052 - ADR
We assign a fundamental rating of 1 out of 10 to BLRX. BLRX was compared to 565 industry peers in the Biotechnology industry. BLRX may be in some trouble as it scores bad on both profitability and health. BLRX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BLRX had negative earnings in the past year.
BLRX had a negative operating cash flow in the past year.
In the past 5 years BLRX always reported negative net income.
In the past 5 years BLRX always reported negative operating cash flow.
1.2 Ratios
BLRX's Return On Assets of -95.25% is on the low side compared to the rest of the industry. BLRX is outperformed by 74.51% of its industry peers.
With a Return On Equity value of -376.32%, BLRX is not doing good in the industry: 77.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -95.25% | ||
| ROE | -376.32% | ||
| ROIC | N/A |
ROA(3y)-53.58%
ROA(5y)-54.34%
ROE(3y)-182.4%
ROE(5y)-151.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLRX's Gross Margin of 9.51% is fine compared to the rest of the industry. BLRX outperforms 73.98% of its industry peers.
BLRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 9.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLRX has more shares outstanding than it did 1 year ago.
BLRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BLRX has a worse debt to assets ratio.
2.2 Solvency
BLRX has an Altman-Z score of -12.00. This is a bad value and indicates that BLRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BLRX (-12.00) is worse than 78.41% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that BLRX is somewhat dependend on debt financing.
BLRX's Debt to Equity ratio of 0.55 is on the low side compared to the rest of the industry. BLRX is outperformed by 74.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
BLRX has a Current Ratio of 1.14. This is a normal value and indicates that BLRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.14, BLRX is not doing good in the industry: 85.49% of the companies in the same industry are doing better.
BLRX has a Quick Ratio of 1.05. This is a normal value and indicates that BLRX is financially healthy and should not expect problems in meeting its short term obligations.
BLRX has a worse Quick ratio (1.05) than 86.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.05 |
3. Growth
3.1 Past
BLRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.32%.
EPS 1Y (TTM)-30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
BLRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOLINERX LTD-SPONS ADR
NASDAQ:BLRX (12/20/2024, 8:00:01 PM)
After market: 0.2084 +0.01 (+2.66%)0.203
+0 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.09%
Inst Owner Change-22.07%
Ins Owners0.34%
Ins Owner ChangeN/A
Market Cap17.07M
Analysts100
Price TargetN/A
Short Float %0.07%
Short Ratio0.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.66
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.14
BVpS0.16
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -95.25% | ||
| ROE | -376.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 9.51% | ||
| FCFM | N/A |
ROA(3y)-53.58%
ROA(5y)-54.34%
ROE(3y)-182.4%
ROE(5y)-151.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.89% | ||
| Cap/Sales | 1.72% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z | -12 |
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)27.86%
Cap/Depr(5y)18.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.14%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.17%
OCF growth 3YN/A
OCF growth 5YN/A